Answers are grounded in this paper and cite their sources.
Our study represents a step toward personalized immunotherapy for patients with TNBC. Immune checkpoint inhibitors might be effective for "immune-inflamed" cluster, and the transformation of "cold tumors" into "hot tumors" should be considered for "immune-desert" and "innate immune-inactivated" clusters.
No takes yet. Share an insight, caveat, or question.
Xiao et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: